Canakinumab-话题@MedSci - 梅斯（MedSci）

#Canakinumab#

7篇内容 | 1095人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1489905, encodeId=dfbc148990531, content=<a href='/topic/show?id=df9b4013cd' target=_blank style='color:#2F92EE;'>#Canakinumab#</a>, objectTitle=诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率, objectType=article, longId=203185, objectId=8a9e203185f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a9e203185f0, replyNumber=0, likeNumber=93, createdTime=2020-11-11, rootId=0, userName=guihongzh, userId=3ccf8632405, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a9e203185f0, moduleTitle=诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8a9e203185f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1489904, encodeId=b862148990496, content=<a href='/topic/show?id=df9b4013cd' target=_blank style='color:#2F92EE;'>#Canakinumab#</a>, objectTitle=Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用, objectType=article, longId=198102, objectId=91da198102bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91da198102bf, replyNumber=0, likeNumber=86, createdTime=2020-07-28, rootId=0, userName=guihongzh, userId=3ccf8632405, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91da198102bf, moduleTitle=Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=91da198102bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1489903, encodeId=01e01489903fa, content=<a href='/topic/show?id=df9b4013cd' target=_blank style='color:#2F92EE;'>#Canakinumab#</a>, objectTitle=FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab, objectType=article, longId=196063, objectId=e34d196063ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e34d196063ce, replyNumber=0, likeNumber=67, createdTime=2020-06-19, rootId=0, userName=guihongzh, userId=3ccf8632405, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e34d196063ce, moduleTitle=FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e34d196063ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1489902, encodeId=f59014899024f, content=<a href='/topic/show?id=df9b4013cd' target=_blank style='color:#2F92EE;'>#Canakinumab#</a>, objectTitle=IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴, objectType=article, longId=193314, objectId=6b1119331457, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b1119331457, replyNumber=0, likeNumber=58, createdTime=2020-05-03, rootId=0, userName=guihongzh, userId=3ccf8632405, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1119331457, moduleTitle=IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6b1119331457)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1489901, encodeId=19a3148990113, content=<a href='/topic/show?id=df9b4013cd' target=_blank style='color:#2F92EE;'>#Canakinumab#</a>, objectTitle=Canakinumab可将痛风发生率降低一半以上, objectType=article, longId=141553, objectId=6dc41415536a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dc41415536a, replyNumber=0, likeNumber=77, createdTime=2018-06-26, rootId=0, userName=guihongzh, userId=3ccf8632405, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dc41415536a, moduleTitle=Canakinumab可将痛风发生率降低一半以上, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6dc41415536a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1489900, encodeId=17471489900fe, content=<a href='/topic/show?id=df9b4013cd' target=_blank style='color:#2F92EE;'>#Canakinumab#</a>, objectTitle=JACC：Canakinumab对动脉粥样硬化患者的血管结构或功能无显著影响, objectType=article, longId=79950, objectId=078fe9950a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=078fe9950a5, replyNumber=0, likeNumber=69, createdTime=2016-10-14, rootId=0, userName=guihongzh, userId=3ccf8632405, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=078fe9950a5, moduleTitle=JACC：Canakinumab对动脉粥样硬化患者的血管结构或功能无显著影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=078fe9950a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1489899, encodeId=881c14898994b, content=<a href='/topic/show?id=df9b4013cd' target=_blank style='color:#2F92EE;'>#Canakinumab#</a>, objectTitle=NEJM：Canakinumab可有效治疗全身型幼年特发性关节炎, objectType=article, longId=18359, objectId=495b1835965, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=495b1835965, replyNumber=0, likeNumber=57, createdTime=2013-05-08, rootId=0, userName=guihongzh, userId=3ccf8632405, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=495b1835965, moduleTitle=NEJM：Canakinumab可有效治疗全身型幼年特发性关节炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=495b1835965)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Canakinumab

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#Canakinumab#

诺华IL-1β单抗canakinumab治疗新冠COVID-19：未能提高生存率

2020-11-11

guihongzh (审核中...)

前往app查看评论内容

#Canakinumab#

Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用

2020-07-28

guihongzh (审核中...)

前往app查看评论内容

#Canakinumab#

FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab

2020-06-19

guihongzh (审核中...)

前往app查看评论内容

#Canakinumab#

IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴

2020-05-03

guihongzh (审核中...)

前往app查看评论内容

#Canakinumab#

Canakinumab可将痛风发生率降低一半以上

2018-06-26

guihongzh (审核中...)

前往app查看评论内容

#Canakinumab#

JACC：Canakinumab对动脉粥样硬化患者的血管结构或功能无显著影响

2016-10-14

guihongzh (审核中...)

前往app查看评论内容

#Canakinumab#

NEJM：Canakinumab可有效治疗全身型幼年特发性关节炎

2013-05-08

科室
- - 订阅+
  - 更多科室
工具
服务